Long Shortz with Lumos: US$317M deal sets new benchmark for ASX diagnostics

Tylah Tully chats with Lumos Diagnostics (ASX:LDX) CEO Doug Ward after the company inked one of the largest distribution deals ever for an ASX-listed point-of-care diagnostics company.

The exclusive US$317 million agreement with PHASE Scientific is a landmark for Lumos as it progresses FebriDx through the FDA CLIA waiver process, oping doors to a further billion-dollar US market.

Ward also shares insight into BARDA’s $8.3 million funding, the importance of antimicrobial stewardship, and what’s next for Lumos – including updates on paediatric trials and a next-gen partnership with Hologic.

This video was developed in collaboration with Lumos Diagnostics, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.